{"product_id":"globalcordbloodcorp-business-model-canvas","title":"Global Cord Blood Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Cord Blood: Strategic Business Model Canvas for Investors \u0026amp; Founders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the full strategic blueprint behind Global Cord Blood's business model—this in-depth Business Model Canvas reveals how the company creates value, scales operations, and monetizes services in a competitive stem-cell market; perfect for investors, consultants, and founders seeking actionable strategy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLicensed Hospital Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe company holds contracts with 120 licensed hospitals across 14 regions to collect cord blood at delivery, giving access to roughly 65,000 births annually where it operates; trained hospital staff follow the firm’s collection protocol, boosting sample quality and reducing failed collections to under 3% in 2024. By late 2025 these partnerships remain the main customer-acquisition channel and account for ~78% of new sign-ups and operational throughput.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment Health Authorities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpas a highly regulated sector in china the company maintains close ties with provincial health bureaus to retain exclusive or semi-exclusive licenses covering specific territories which reduced license nonrenewal risk under for leading cord operators. these partnerships keep operations aligned evolving healthcare policies and national biosecurity standards audits occurred quarterly cost annually ensuring market access regulatory continuity.\u003e\n\u003c\/pas\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical Research Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCollaborations with universities and stem cell centers (eg, Johns Hopkins, Karolinska) fund trials that expanded cord blood indications by 23% from 2019–2024; partners validate long-term efficacy via 10+ year follow-ups and pilot studies treating leukemias and genetic disorders, boosting R\u0026amp;D credibility and helping commercial leads where joint grants averaged $2.1M per project in 2023.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInsurance and Financial Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBy late 2025, cord blood firms routinely partner with insurers and financial providers to bundle storage with transplant coverage, with ~40% of top-10 global banks\/insurers offering such packages and claim payout guarantees up to $200k per eligible treatment.\u003c\/p\u003e\n\u003cp\u003eThese partnerships position storage as a financial-planning tool, lowering out-of-pocket transplant risk and increasing parental purchase likelihood by ~25% in market trials.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~40% top-10 insurers offer bundles\u003c\/li\u003e\n\u003cli\u003eCoverage up to $200,000 per treatment\u003c\/li\u003e\n\u003cli\u003eParental purchase uplift ~25%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLogistics and Cold Chain Specialists\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLogistics partners with validated cold chain systems ensure cord blood reaches processing labs within 24 hours, keeping temperatures at -80°C to -196°C as needed; studies show timely transport preserves \u0026gt;90% stem cell viability, cutting sample loss risk by over 70% versus non-specialized carriers.\u003c\/p\u003e\n\u003cp\u003eReliable providers often add 24\/7 tracking, fail-safe backup power, and cost per shipment of $150–$400 in 2025, making cold chain management a non-negotiable operational expense for global cord blood programs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e24-hour transit standard\u003c\/li\u003e\n\u003cli\u003eTemperature range -80°C to -196°C\u003c\/li\u003e\n\u003cli\u003e\u0026gt;90% viability with proper handling\u003c\/li\u003e\n\u003cli\u003e70% lower loss vs non-specialized\u003c\/li\u003e\n\u003cli\u003e$150–$400 per shipment (2025)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e120-hospital network captures ~65K births\/yr, low collections \u0026amp; 25% insurer lift\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eContracts with 120 hospitals across 14 regions capture ~65,000 births\/year; failed collections \u0026lt;3% (2024). Provincial health bureaus cut license nonrenewal risk \u0026lt;5% and compliance audits cost ~RMB 1.2M\/year. Univ.\/centers expanded indications +23% (2019–2024); grants ~$2.1M\/project (2023). Insurer bundles lift purchase rates ~25%; logistics: 24h transit, \u0026gt;90% viability, $150–$400\/shipment (2025).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals\u003c\/td\u003e\n\u003ctd\u003e120\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBirths\/year\u003c\/td\u003e\n\u003ctd\u003e~65,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFailed collections\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;3%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAudit cost\u003c\/td\u003e\n\u003ctd\u003eRMB 1.2M\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIndication growth\u003c\/td\u003e\n\u003ctd\u003e+23% (2019–24)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGrant size\u003c\/td\u003e\n\u003ctd\u003e$2.1M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInsurer lift\u003c\/td\u003e\n\u003ctd\u003e+25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eShipment cost\u003c\/td\u003e\n\u003ctd\u003e$150–$400\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, pre-built Global Cord Blood Business Model Canvas detailing customer segments, channels, value propositions, revenue streams, key activities, resources, partners, cost structure, and metrics, aligned to real-world operations and investor needs for presentations and funding discussions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level, editable one-page Business Model Canvas for the global cord blood industry that quickly maps value propositions, partners, channels, and revenue streams to relieve strategic planning pain points and accelerate team collaboration.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStem Cell Processing and Testing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOnce collected, cord blood undergoes validated lab testing and processing to isolate hematopoietic stem cells; our GMP facilities deliver \u0026gt;95% purity and median CD34+ counts of 3.2×10^6 cells\/unit (2025 internal KPI). Automated closed-system platforms cut processing errors by 78% and sustain throughput above 25,000 samples\/year, supporting unit revenue of ~$1,200 per processed sample and ISO 20387-aligned traceability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCryogenic Storage and Maintenance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe core activity is long-term preservation of hematopoietic and mesenchymal stem cells in liquid nitrogen vapor at −150°C to −196°C, with 24\/7 telemetry and alarm systems; in 2025 the company stores over 1.2 million cord blood units across 12 global cryobanks. \u003c\/p\u003e\n\u003cp\u003eOperations include redundant gensets and UPS, quarterly tank maintenance, and barcode\/RFID inventory systems—storage failures cost firms up to $10M per major loss event, so uptime targets exceed 99.99%. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSales and Educational Marketing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eA large share of resources goes to educating expectant parents on cord blood banking benefits; hospital-based sales teams provide face-to-face consultations and pitch the service as long-term medical insurance, with China-specific materials addressing prevalent concerns (e.g., 1 in 5 couples cite genetic disease risk) and cultural trust drivers; market spend in China reached about $220M in 2024, with hospital-conversion rates near 12% in tier-1 cities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Compliance and Quality Control\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eContinuous monitoring of lab standards and laws—via quarterly internal audits, annual external AABB (American Association of Blood Banks) inspections, and monthly equipment calibration—keeps operating licenses active and reduces regulatory fine risk (average noncompliance fine in biotech was $1.2M in 2024).\u003c\/p\u003e\n\u003cp\u003eHigh-quality control is non-negotiable for brand trust and payer contracts, with \u0026gt;99.5% viability target for stored cord blood units and CAP\/AABB accreditation affecting 12–18% higher retention in private banking.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eQuarterly internal audits\u003c\/li\u003e\n\u003cli\u003eAnnual AABB\/CAP inspections\u003c\/li\u003e\n\u003cli\u003eMonthly equipment calibration\u003c\/li\u003e\n\u003cli\u003eTarget \u0026gt;99.5% cell viability\u003c\/li\u003e\n\u003cli\u003eMitigates ~$1.2M average fine risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe company allocates ~8–12% of annual revenue to R and D, targeting improved cryopreservation that extends viable stem cell recovery from 15 to 25 years and trials to preserve cord tissue and mesenchymal stem cells for orthopedic and autoimmune indications.\u003c\/p\u003e\n\u003cp\u003eOngoing studies and partnerships with 3 university centers keep the firm in cellular-therapy pipelines, aiming for 20–30% service-line revenue growth from tissue-based products by 2028.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eR and D spend: 8–12% revenue\u003c\/li\u003e\n\u003cli\u003eTarget storage life: 25 years viable recovery\u003c\/li\u003e\n\u003cli\u003eExpanding to cord tissue, MSCs\u003c\/li\u003e\n\u003cli\u003e3 academic research partners\u003c\/li\u003e\n\u003cli\u003eGoal: 20–30% revenue from tissue by 2028\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLeading GMP Stem Cell Processing: 1.2M Units, 95%+ Purity, $1.2K\/unit\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCore activities: GMP processing (95%+ purity; median CD34+ 3.2×10^6\/unit, 2025), cryostorage of 1.2M units across 12 banks at −150° to −196°C with 99.99% uptime, regulatory QA (quarterly audits, annual AABB\/CAP), 8–12% revenue R\u0026amp;D targeting 25‑yr viability and tissue\/MSCs expansion. \u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUnits stored\u003c\/td\u003e\n\u003ctd\u003e1.2M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCD34+ median\u003c\/td\u003e\n\u003ctd\u003e3.2×10^6\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProcessing revenue\/unit\u003c\/td\u003e\n\u003ctd\u003e$1,200\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e8–12% rev\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document you're previewing is the exact Global Cord Blood Business Model Canvas you’ll receive after purchase—not a mockup or sample—and is fully structured for immediate use.\u003c\/p\u003e\n\u003cp\u003eWhen you complete your order, you’ll get this same professional file, complete and downloadable, ready to edit, present, or integrate into your strategic work.\u003c\/p\u003e\n\u003cp\u003eNo surprises or placeholders—what you see here is the real deliverable, formatted and comprehensive for practical application.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56749700907385,"sku":"globalcordbloodcorp-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/globalcordbloodcorp-business-model-canvas.png?v=1772217263","url":"https:\/\/matrixbcg.com\/products\/globalcordbloodcorp-business-model-canvas","provider":"MatrixBCG","version":"1.0","type":"link"}